Daniel J. Klein

President and Chief Executive Officer, Patient Access Network Foundation, Washington, DC

Authored Items

Who Exactly Would Benefit from Lower Cost of Cancer Drugs?

July 2015, Vol 6, No 6 - VBCC Perspectives

The high costs of specialty medications and the burden they place on individual patients and on the healthcare system overall are the media topics du jour. Cancer drugs are often cited as examples of unrestrained medication costs, so it is not surprising that the oncology community has responded by proposing alternative pricing models for cancer treatments based on the incremental value they provide. [ Read More ]